Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IoM seeks to augment Enzi/Kennedy bill

Executive Summary

The Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System seeks to work with Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.) on their "Enhancing Drug Safety & Innovation Act." "We certainly hope that when they start negotiations over that bill that the chair of our committee can go and testify in Congress and the bill can incorporate more of what is in the committee report," IoM Committee Study Director Kathleen Stratton said at the Academy of Managed Care Pharmacy Educational Conference Oct. 6. The committee's report, released in September, calls for sweeping changes at FDA (1The Pink Sheet" Oct. 2, 2006, p. 5)...

You may also be interested in...



FDA Drug Safety Reforms Not Enough To Fix Problems, IoM Committee Says

A separate postmarketing safety center may become necessary if the recommendations made by the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System do not result in sufficient reforms of FDA's safety oversight, the committee says

Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'

The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.

Broad Heart Failure Label Ushers Lexicon’s Inpefa Into SGLT2 Inhibitor Market

Sotagliflozin’s cardiovascular outcomes trials support the most expansive heart failure risk reduction claim approved by the US FDA in the class, a turnaround from the drug’s setbacks in type 1 diabetes.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel